🍽️ diclofenac sodium,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Pain Relief: Diclofenac sodium is effective in relieving mild to moderate pain associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, musculoskeletal injuries, menstrual cramps, and postoperative pain. It works by inhibiting the production of prostaglandins, which are chemicals in the body that promote inflammation and pain.

  2. Anti-inflammatory Action: Diclofenac sodium has potent anti-inflammatory properties, making it useful for reducing inflammation associated with various inflammatory conditions, including arthritis, bursitis, tendonitis, and other musculoskeletal disorders. By inhibiting the synthesis of prostaglandins, diclofenac sodium helps decrease swelling, tenderness, and stiffness in affected joints and tissues.

  3. Fever Reduction: In addition to its analgesic and anti-inflammatory effects, diclofenac sodium can also reduce fever by inhibiting the production of prostaglandins in the brain's hypothalamus, which regulates body temperature. It may be used to alleviate fever associated with infections, inflammatory conditions, or other causes.

  4. Dosage Forms: Diclofenac sodium is available in various dosage forms, including tablets, capsules, extended-release tablets, and topical formulations such as gels, creams, and patches. The choice of dosage form depends on the specific medical condition being treated, the severity of symptoms, and individual patient preferences and needs.

  5. Topical Application: Topical diclofenac formulations are commonly used to provide localized pain relief and inflammation reduction in specific areas of the body, such as the joints (e.g., knees, elbows) affected by osteoarthritis or other musculoskeletal conditions. Topical diclofenac is absorbed through the skin and penetrates deeply into the underlying tissues to provide targeted relief.

  6. Gastrointestinal Effects: Like other NSAIDs, diclofenac sodium can irritate the lining of the stomach and increase the risk of gastrointestinal complications such as ulcers, bleeding, and perforation. To minimize this risk, diclofenac sodium may be prescribed in combination with a proton pump inhibitor (PPI) or a histamine H2-receptor antagonist to reduce gastric acid secretion and protect the stomach lining.

  7. Cardiovascular Risks: NSAIDs, including diclofenac sodium, may increase the risk of cardiovascular events such as heart attack or stroke, particularly with long-term use or in individuals with pre-existing cardiovascular disease. It's essential to use the lowest effective dose of diclofenac sodium for the shortest duration necessary to control symptoms and to regularly monitor cardiovascular risk factors in individuals taking this medication.

  8. Kidney Function: Diclofenac sodium can affect kidney function, especially in individuals with pre-existing kidney disease or conditions that affect renal blood flow. Regular monitoring of kidney function, including serum creatinine levels and urine output, may be necessary in individuals taking diclofenac sodium, particularly for long-term use or in those with risk factors for kidney dysfunction.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of diclofenac sodium,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by diclofenac sodium,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Odoribacter genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Bifidobacterium genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Roseburia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Streptococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Coprococcus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Veillonella parvula species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Lachnospira eligens species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Coprococcus comes species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of diclofenac sodium,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.4 -0.4
ADHD 5.3 0.4 12.25
Age-Related Macular Degeneration and Glaucoma 0.5 0.3 0.67
Allergic Rhinitis (Hay Fever) 0.8 1.9 -1.37
Allergies 4.5 2.1 1.14
Allergy to milk products 0.7 0.7 0
Alopecia (Hair Loss) 1.8 1.8
Alzheimer's disease 3.5 4.4 -0.26
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.9 0.9 2.22
Ankylosing spondylitis 3 1.5 1
Anorexia Nervosa 0.3 1.8 -5
Antiphospholipid syndrome (APS) 1.3 1.3
Asthma 1.2 1.5 -0.25
Atherosclerosis 1.5 1.6 -0.07
Atrial fibrillation 2.9 1.2 1.42
Autism 7.3 6.9 0.06
Barrett esophagus cancer 0.8 0.3 1.67
benign prostatic hyperplasia 0 0
Bipolar Disorder 1 1.5 -0.5
Brain Trauma 0.8 0.7 0.14
Carcinoma 3.4 2.7 0.26
Celiac Disease 1.5 4.2 -1.8
Cerebral Palsy 1.4 1.4 0
Chronic Fatigue Syndrome 4.7 4.7 0
Chronic Kidney Disease 1.6 1.2 0.33
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 2.2 0.6 2.67
Chronic Urticaria (Hives) 0.7 1.2 -0.71
Coagulation / Micro clot triggering bacteria 0.6 1.4 -1.33
Colorectal Cancer 4.8 0.9 4.33
Constipation 0.6 0.7 -0.17
Coronary artery disease 1 0.7 0.43
COVID-19 11.6 12.3 -0.06
Crohn's Disease 6.5 5.3 0.23
cystic fibrosis 0 1.1 0
deep vein thrombosis 0 1 0
Depression 9.2 6.2 0.48
Dermatomyositis 0.3 0.4 -0.33
Eczema 0.5 2.1 -3.2
Endometriosis 1.8 1.5 0.2
Eosinophilic Esophagitis 0.4 0.4 0
Epilepsy 2.9 2.4 0.21
Fibromyalgia 2.1 1.4 0.5
Functional constipation / chronic idiopathic constipation 4 2.5 0.6
gallstone disease (gsd) 1.5 1.2 0.25
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.3 1 0.3
Generalized anxiety disorder 0.9 1.7 -0.89
giant cell arteritis 0 0
Glioblastoma 0.3 -0.3
Gout 0 0
Graves' disease 1.4 1.2 0.17
Halitosis 1.1 0.3 2.67
Hashimoto's thyroiditis 2.3 0.7 2.29
Hidradenitis Suppurativa 0.7 0.4 0.75
Histamine Issues,Mast Cell Issue, DAO Insufficiency 2.6 0.6 3.33
hypercholesterolemia (High Cholesterol) 0.5 0.6 -0.2
hyperglycemia 0 2.2 0
Hyperlipidemia (High Blood Fats) 1 0.4 1.5
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 2.3 4.9 -1.13
Hypothyroidism 1.1 -1.1
Hypoxia 0.9 0.9
IgA nephropathy (IgAN) 3.6 -3.6
Inflammatory Bowel Disease 4 7.2 -0.8
Insomnia 0.9 0.9 0
Intelligence 0.5 0.1 4
Intracranial aneurysms 1.3 0.4 2.25
Irritable Bowel Syndrome 3.7 4 -0.08
Liver Cirrhosis 4.1 2.6 0.58
Long COVID 6.6 9 -0.36
Low bone mineral density 0.6 -0.6
Lung Cancer 0.3 1.4 -3.67
ME/CFS with IBS 0.5 1.7 -2.4
ME/CFS without IBS 1.7 2.1 -0.24
Menopause 2.4 2.4
Metabolic Syndrome 6.2 7.9 -0.27
Mood Disorders 11.3 6.6 0.71
multiple chemical sensitivity [MCS] 1.8 0.3 5
Multiple Sclerosis 6.3 4 0.57
Multiple system atrophy (MSA) 1.9 1.1 0.73
Neuropathy (all types) 0.9 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.3 5.1 -2.92
NonCeliac Gluten Sensitivity 0.4 -0.4
Obesity 6.9 4.8 0.44
obsessive-compulsive disorder 5.8 3.1 0.87
Osteoarthritis 1.5 0.4 2.75
Osteoporosis 1.5 1.2 0.25
pancreatic cancer 0.8 0.8
Parkinson's Disease 2.6 3 -0.15
Polycystic ovary syndrome 1.3 2.3 -0.77
Postural orthostatic tachycardia syndrome 0 0.4 0
Premenstrual dysphoric disorder 1.1 0.3 2.67
primary biliary cholangitis 0.1 0.9 -8
Psoriasis 3.6 2.7 0.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 5.6 3.4 0.65
Rosacea 1.2 0.4 2
Schizophrenia 6.3 1.5 3.2
scoliosis 0 0.9 0
Sjögren syndrome 2.7 2.7 0
Sleep Apnea 1.5 1.4 0.07
Small Intestinal Bacterial Overgrowth (SIBO) 0.7 0.9 -0.29
Stress / posttraumatic stress disorder 2.2 2.8 -0.27
Systemic Lupus Erythematosus 3.6 2.2 0.64
Tic Disorder 0.9 1.1 -0.22
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 2.9 1.5 0.93
Type 2 Diabetes 6.2 6.1 0.02
Ulcerative colitis 1.5 4.3 -1.87
Unhealthy Ageing 4.7 1.7 1.76

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.